摘要
Doxorubicin is an anthracycline drug used as frontline chemotherapy of osteosarcoma among other types of cancers.While quite effective in providing a good control over the tumours in some patients,it can cause significant toxicity to organs such as the heart[1].Attempts to ameliorate this toxicity with agents such as dexrazoxane have been successful,but not without complications[2]as will be discussed in this talk.Pigment epithelium-derived factor(PEDF),a potent antiangiogenic and osteogenetic protein[3],was used to reduce this side-effect,together with an analysis of levels of adenosine triphosphate(ATP)and reactive oxygen species(ROS).The effects of low dose doxorubicin in a clinically relevant dosing model will be discussed.
